Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

23.0%

14 terminated/withdrawn out of 61 trials

Success Rate

53.3%

-33.2% vs industry average

Late-Stage Pipeline

10%

6 trials in Phase 3/4

Results Transparency

44%

7 of 16 completed trials have results

Key Signals

14 recruiting7 with results9 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2

30(50.8%)

Phase 1

22(37.3%)

Phase 3

6(10.2%)

Early Phase 1

1(1.7%)

59Total

Phase 2(30)

Phase 1(22)

Phase 3(6)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (61)

Showing 20 of 61 trials

NCT05318469Phase 1Recruiting

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Role: collaborator

NCT05572970Unknown

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Role: lead

NCT05363709Phase 2Active Not Recruiting

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Role: collaborator

NCT06843434Phase 2Recruiting

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Role: collaborator

NCT07152821Phase 3Recruiting

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Role: collaborator

NCT06346197Phase 3Recruiting

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Role: collaborator

NCT04028063Phase 2Active Not Recruiting

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Role: collaborator

NCT05632328Phase 2Active Not Recruiting

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Role: collaborator

NCT07128355Early Phase 1Not Yet Recruiting

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

Role: collaborator

NCT06300463Phase 2Recruiting

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Role: collaborator

NCT03860272Phase 1Active Not Recruiting

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Role: lead

NCT03894215Phase 2Terminated

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Role: lead

NCT06279130Phase 2Recruiting

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Role: collaborator

NCT05928806Phase 2Suspended

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Role: collaborator

NCT07227636Phase 2Recruiting

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Role: collaborator

NCT06268015Phase 2Active Not Recruiting

Botensilimab and Balstilimab Optimization in Colorectal Cancer

Role: collaborator

NCT05529316Phase 2Active Not Recruiting

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Role: lead

NCT06076837Phase 1Active Not Recruiting

The Seven Trial: Exploiting the Unfolded Protein Response

Role: collaborator

NCT06411691Phase 1Recruiting

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Role: collaborator

NCT06782932Phase 1Recruiting

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Role: collaborator